- Risk of Second Primary Cancers After a Diagnosis of First Primary Cancer: A
- 2 Pan-Cancer Analysis and Mendelian Randomization Study
- 4 Xiaohao Ruan^{1†}, Da Huang^{1†}, Yongle Zhan², Jingyi Huang¹, Jinlun Huang¹, Ada
- 5 Tsui-Lin NG², James Hok-Leung TSU², Rong Na^{2*}.
- 7 1. Department of Urology, Ruijin Hospital, Shanghai Jiao Tong University School of
- 8 Medicine, Shanghai 200025, China.
- 9 2. Division of Urology, Department of Surgery, Queen Mary Hospital, The University
- of Hong Kong, Hong Kong, China.
- [†] Xiaohao Ruan and Da Huang contributed equally to this work.
- 12 *Corresponding Author.
- 13 Rong Na,

3

6

- 14 Division of Urology, Department of Surgery, Queen Mary Hospital, The University of
- 15 Hong Kong, Hong Kong, China
- Tel: +852-22554310; Email address: <u>narong.hs@gmail.com</u>.
- 17 No. of Words:
- 18 Abstract: 238 words
- 19 Text: 2956 words

20

21

Abstract

42

22 23 **Background**: The risk of second primary cancers (SPC) is increasing after the first 24 primary cancers (FPC) are diagnosed and treated. The underlying causal relationship 25 remains unclear. 26 **Methods**: We conducted a pan-cancer association (26 cancers) study in the 27 Surveillance, Epidemiology, and End Results (SEER) database. The standardized 28 incidence ratio (SIR) was estimated as the risk of SPCs in cancer survivors based on the 29 incidence in the general population. Furthermore, the causal effect was evaluated by 30 two-sample Mendelian Randomization (MR, 13 FPCs) in the UK Biobank (UKB, 31 n=459,136) and robust analysis (radial MR and Causal Analysis Using Summary Effect 32 estimates, CAUSE). 33 **Results**: We found 11 significant cross-correlations among different cancers after 34 harmonizing SIR and MR results. Whereas only 4 of them were confirmed by MR to 35 have a robust causal relationship. In particular, patients initially diagnosed with oral 36 pharyngeal cancer would have an increased risk of non-Hodgkin lymphoma 37 (SIR_{SEER}=1.18, 95%Confidence Interval [CI]:1.05-1.31, OR_{radial-MR}=1.21, 95%CI:1.13-1.30, $P=6.00\times10^{-3}$; OR_{cause}=1.17, 95%CI:1.05-1.31, $P=8.90\times10^{-3}$). 38 39 Meanwhile, ovary cancer was identified to be a risk factor for soft tissue cancer 40 (SIR_{SEER}=1.72, 95%Confidence Interval [CI]:1.08-2.60, OR_{radial-MR}=1.39, 41 95%CI:1.22-1.58, $P=1.07\times10^{-3}$; OR_{cause}=1.36, 95%CI:1.16-1.58, P=0.01). And kidney

cancer was likely to cause the development of lung cancer (SIR_{SEER}=1.28,

- 43 95%Confidence Interval [CI]:1.22-1.35, OR_{radial-MR}=1.17, 95%CI:1.08-1.27,
- 44 $P=6.60\times10^{-3}$; OR_{cause}=1.16, 95%CI:1.02-1.31, P=0.05) and myeloma (SIR_{SEER}=1.54,
- 45 95%Confidence Interval [CI]:1.33-1.78, OR_{radial-MR}=1.24, 95%CI:1.21-2.45, *P*=0.02;
- 46 OR_{cause}=1.49, 95%CI:1.04-2.34, *P*=0.02).
- 47 **Conclusions**: A certain type of primary cancer may cause another second primary
- cancer, and the profound mechanisms need to be studied in the future.
- 49 **Funding:** This work was in supported by grants from National Natural Science
- 50 Foundation of China (Grant No. 81972645), Innovative research team of high-level
- 51 local universities in Shanghai, Shanghai Youth Talent Support Program, intramural
- 52 grant of The University of Hong Kong to Dr. Rong Na, and Shanghai Sailing Program
- 53 (22YF1440500) to Dr. Da Huang.
- 54 **Keywords**: First primary cancer; Mendelian Randomization study; Pan-cancer
- analysis; Second primary cancer.

Introduction

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

Cancer incidence is rapidly growing worldwide in the past decades. The reasons are complex including the aging of the population, the application of screening, environmental risk factors and genetic risk factors(Sung et al., 2021). In 2020, there were an estimated 19.3 million new cases and 10.0 million deaths of different types of cancers globally(Sung et al., 2021). In the US, there would be about 1.9 million new cases of cancers in 2022, and the most common type of cancers in the male and the female were prostate cancer (27%) and breast cancer (31%), respectively (Siegel et al., 2022). Despite the rapidly increased incidence of cancers, the survival of (most types of) cancers in the US has vastly improved since the mid-1970s with medical advances and technical developments(Siegel et al., 2022). For example, the 5-year relative survival rates of prostate cancer, melanoma, and female breast cancer, during 2011-2017 in the US were 98%, 93%, and 90%, respectively (Siegel et al., 2022). Such disparity may lead to an increase in the prevalence and the tumor burden in US society. More importantly, prolonged survival makes it possible for individuals to be diagnosed with a second primary cancer (SPC) after the first primary cancer (FPC) during the follow-up. According to the Italian (1976-2010)("Italian cancer figures, report 2013: Multiple tumours," 2013), the Swiss (1981-2009)(Feller et al., 2020), and the Swedish (1990-2015)(Zheng et al., 2020) cancer registration data, increased risks of SPCs were observed in many types of cancer as the FPCs. Patients with oral cavity & pharynx, larynx, and esophagus as FPC were found to have a significantly elevated risk of any

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

SPCs in both Italy and Switzerland(Feller et al., 2020; "Italian cancer figures, report 2013: Multiple tumours," 2013). In Sweden, liver cancers, as well as nasal and oral cancers, were found to be associated with SPCs(Zheng et al., 2020). In addition, several studies focused on certain cancer also suggested a potential relationship between FPC and SPC(Chattopadhyay et al., 2018). For example, increased FPC risk of colorectal cancer, kidney cancer, and melanoma were observed following the diagnosis of non-Hodgkin lymphoma. Despite the strong association observed in these studies, whether there is any underlying causal relationship is unknown, or the association observed is due to the potential confounders such as aging. In the present study, our objectives are to perform a pan-cancer association study in the Surveillance, Epidemiology, and End Results (SEER) and to interpret the underlying causal relationship via Mendelian Randomization approaches using genetic variants in a large population cohort (UK Biobank, UKB). In addition, the study may also help us understand critical questions in clinical practice about who should be more careful of the second primaries, and who should take precision screenings against certain cancers in addition to the regular follow-up evaluations. Results We set out to identify the observational association between FPCs and SPCs among 22 solid tumors and 4 hematological malignancies based on the SEER database (Figure 1). A total of 264 significant standardized incidence ratio (SIR)

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

existed among them when compared to a standard population (Table S1-17). Hierarchical clustering analysis (heatmap) is shown in Figure 2 which illustrates the comparison between the cancer incidence in patients with a certain type of FPC and the incidence in the population average level in the SEER dataset. Second primary thyroid cancer, small bowel cancer, or cancers of endocrine system were strongly and significantly associated with most of the FPCs. Cancers of the digestive system, cervix uteri, as well as lung cancer were clustered together. They are closely correlated with an increased risk of several types of cancers such as bladder cancer, kidney cancer, etc. Our subgroup analysis suggested that patients with prostate cancer who received radiation therapy were at an increased risk of being diagnosed with another type of primary cancer during the follow-up including small intestine, soft tissue, and leukemia, compared with those without such therapy (Table S13). And SPC risk after breast cancer was inconsistent among males and females. Men with breast cancer had a higher risk for thyroid cancer and prostate cancer (SIR_{SEER}=1.30; 95% CI, 1.13-1.49; SIR_{SEER}=2.33, 1.12-4.29; **Table S10**), but with no significant risk change for other cancers. Details of the included exposure-associated SNPs in European ancestry were shown in Table 1 and Table S18. The number of SNPs ranged from 5 (esophagus) to 104 (female breast), and the proportion of variance explained by SNPs (R²) ranged from 0.10% (thyroid) to 8.46% (bladder). F-statistics for all 13 cancers exceeded 10, suggesting no weak instrument bias here. However, some problems, including too few

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

SNPs, no related GWAS and disease heterogeneity, affected the comprehensive MR analysis (Table 1). Due to the low incidence of cancers in UKB, the power to detect a significant effective size (0.8/1.2) was relatively low, except for colorectal cancer, lung cancer, female breast cancer and prostate cancer (Table S19). Results from MR analyses are presented in **Table S20-33**. A total of 23 significant association was detected (16 positive causality and 7 negative causality). Concordant significant results and unconcordant results between MR and the SEER SIR analyses are shown in Table 2 and Table S20, respectively. The concordant results suggested that patients diagnosed with primary oral and pharynx cancer would cause a significantly increased risk of second primary non-Hodgkin lymphoma (SIR_{SEER}=1.18, 95% CI: 1.05-1.31; IVW-MR $P=8.96\times10^{-4}$). After a primary diagnosis of pancreatic cancer, SPC risks were increased for small intestine (SIR_{SEER}=4.37, 95% CI: 2.85-6.40; MR-Egger P=0.04). It also indicated that female patients initially diagnosed with melanoma would cause a mild but significantly increased risk of cancers in the breast (SIR_{SEER}=1.17, 95% CI: 1.12-1.23; IVW-MR *P*=0.04), as well as ovary cancer on soft tissue related cancer (SIR_{SEER}=1.72, 95% CI: 1.08-2.60; IVW-MR P=8.39×10⁻⁵). The greatest number of casual relationships were observed in kidney cancer as FPC. A primary kidney cancer might cause an elevated risk of cancers of lung and bronchus (SIR_{SEER}=1.28, 95% CI: 1.23-1.45; IVW-MR *P*=0.01), non-Hodgkin lymphoma $(SIR_{SEER}=1.19, 95\% CI: 1.08-1.31; IVW-MR P=3.64\times10^{-3}), myeloma (SIR_{SEER}=1.54,$ 95% CI: 1.33-1.78; IVW-MR $P=3.94\times10^{-3}$). Meanwhile, some primary cancer site

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

might give protective effect against another cancer (for instance, lung cancer vs. female breast cancer, Table 2). Scatter plot, Funnel plot, forest plot and leave-one-out analysis showed single SNP effective size in Figure S1-4, respectively. More conservative analyses were performed to further confirm these causal relationships. We applied 2 outlier-detected methods with modified second order weights (radial IVW and radial MR-Egger) and CAUSE (Causal Analysis Using Summary Effect estimates) to each pair of phenotypes, with the rationale that robust relationships would exhibit consistent and statistically significant results across different methods. Additionally, CAUSE is the only method capable of distinguishing causality from both correlated and uncorrelated pleiotropy. The relationship with at least 2 significant results was treated as a robust causality (Table 3). We found consistent evidence for a causal effect of oral and pharynx cancer on non-Hodgkin lymphoma ($P_{radial-IVW} = 6.00 \times 10^{-3}$, $P_{cause} = 8.90 \times 10^{-3}$), ovary cancer on soft tissue cancer $(P_{radial-IVW}=1.07\times10^{-3}, P_{cause}=0.01)$, kidney cancer on lung and myeloma $(P_{radial-IVW}=1.07\times10^{-3}, P_{cause}=0.01)$ 6.60×10^{-3} , $P_{cause}=0.05$; $P_{radial-IVW}=0.02$, $P_{cause}=0.02$). Discussion With the expanded life expectancy and the prolonged survival of cancers, the incidence of SPCs has been rapidly growing in the past decades (Copur & Manapuram, 2019). Genetic factors or shared environmental factors are probably the major causes. In the previous association studies, individuals with a certain type of primary

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

malignancy would have an increased risk of another malignancy(Feller et al., 2020; "Italian cancer figures, report 2013: Multiple tumours," 2013; Zheng et al., 2020). However, whether there are any causal effects within the associations is unclear. In the present study, via the association study based on the SEER database and the MR approach using the UKB genetic dataset, we were able to perform this comprehensive investigation across 26 different types of cancers. 13 out of 26 types of cancers with adequate GWAS data were able to be further investigated using MR analysis. We found that numbers of primary malignancies were associated with an increased risk of a second primary malignancy, however, only a small part of the associations would have a causal relationship (Table 2). Many significant findings were observed in the SEER SIR analysis. SEER is one of the largest cancer registration-based datasets making itself the most proper data source to answer the study objectives; however, several advantages of this database and limitations of the results should be noted. First, the results from the SEER SIR analysis were associations rather than causal inferences. Many factors may influence the results of the associations. For example, the confounder of screening effects may exist. Patients diagnosed with primary cancer might have more frequent healthcare visits compared to those who did not have any cancers. Therefore, some indolent cancers such as thyroid cancer and low-risk prostate cancer could have been over-diagnosed due to the screening effects. Second, it is a cancer registration-based cohort rather than a population cohort, the standardized incidences calculated from the SEER database

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

may not represent the situation in the general population. Third, treatment preferences and follow-up strategies may vary in different locations or institutions, which would also affect the occurrence/detection of the second primary cancer. For example, radiation therapy may increase the risk of cancer in nearby organs⁶. However, treatment and follow-up information are not completed in the SEER database due to the natural design of the cohort³¹. More importantly, lifestyles, comorbidities, and environmental factors were not included in the SEER database. These are important confounders of the associations between the first primary cancers and the second primary cancers. The MR approaches in the current study revealed some interesting findings, but several non-concordant results between MR analyses and SEER SIR were also observed (Table S20). It does not indicate that the causal relationship does not exist. Some factors, such as the period of follow-up, may conceal and cause false negatives in the association study (SEER SIR). For example, pancreatic cancer might cause an increased risk of cancers in esophagus, colon and rectum, etc. based on the MR analysis in our study; however, no association was observed in SEER SIR analysis. The short and poor survival of pancreatic cancer could be the most critical reason for the failure of finding a positive association in the population data --- simply did not have enough time of follow-up to observe the outcomes. Therefore, the interpretation of these results should be more careful at this stage. The lack of GWAS findings would be a major limitation of the MR approach for some diseases as in the present study. The MR approach may only represent part of

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

the biological effects in the causal pathway between the exposure and the outcome. A final causal inference should always be established based on biological mechanisms. From the angle of organ location, some cancers (ovary cancer and soft tissue sarcoma) might share the same tumor-related or tumor-developing environment. Besides the outside therapeutic settings (radio- and chemotherapy, immuno-suppressive agents) and individual factors (smoking, hormone level, certain occupational settings, HIV or HPV infections, and family histories), FPC might also influence the iatrogenic immune by suppressing antitumor defense mechanisms via inflammation or other meditating effects (Shalapour & Karin, 2019). For instance, the increased risk of renal cancer, and non-Hodgkin lymphoma were observed in immunosuppressed patients in Denmark and Sweden(Hortlund et al., 2017). The immune factor might be the inner relation between FPC and SPC. In our assumption, the question of mechanism should be answered via cross-trait GWAS meta-analyses, searching for shared genetic architecture under high heritability or potential meditation factors with comprehensive database and analyses, functional experiments (tissue- or cell-specific findings) and final validation in a cohort of comorbidity patients. Finally, besides the limitations mentioned, the relatively small number of cases of some diseases in UKB may lower our statistical power. As UKB is a population-based prospective cohort, the relatively short follow-up period may not allow us to observe enough events (multiple cancers) at this stage. And it is expected to be independently replicated in another dataset. Regardless, these findings progress our

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

understanding of the relationship underlying both FPCs and SPCs, and potentially provide points of exploration and intervention that may reduce second primary cancers. Conclusion Patients who were diagnosed with a certain type of primary cancer may cause another type of primary cancer, especially pharynx cancer on non-Hodgkin lymphoma, ovary cancer on soft tissue cancer, kidney cancer on lung and myeloma. The profound mechanisms need to be studied in the future. Methods Study populations SEER Program 18 Registry database was obtained which covered 27.8% of the total population in the United States("Number of Persons by Race and Hispanic Ethnicity for SEER Participants - SEER Registries.,"). The SEER program is the largest cancer incidence dataset in the United States based on population cancer registration. Based on the ICD-10 code, we identified adult patients (age ≥20 years) diagnosed with an FPC between 2000 and 2016, including 22 types of solid-tumor sites (oral cavity and pharynx, esophagus, stomach, small intestine, colon and rectum, liver, gallbladder, pancreas, larynx, lung and bronchus, bones and joints, soft tissue including heart, melanoma of the skin, female breast, male breast, cervix uteri, ovary,

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

prostate, bladder, kidney, renal pelvis and ureter, brain, thyroid) and 4 types of hematological malignancies (Hodgkin lymphoma, non-Hodgkin lymphoma, myeloma, leukemia). Patients with diagnosis by autopsy or mentioned in the death certificate only were excluded. The UKB project is a prospective cohort study collecting phenotypic and genotypic data from ~500,000 individuals from across the United Kingdom (median follow-up time was ~14 years). The participants aged between 40 and 69 at recruitment(Bycroft et al., 2018). In the present study, a total of 459,156 participants with European Ancestry from UKB (release V3) with GWAS genotyping array data and imputation information were obtained and included in the MR analysis. Disease phenotypes in UKB were also defined using the ICD-10 code. Non-Caucasian patients were not included in the present study in SEER or UKB due to the small number of subjects in UKB, which made it hard to make the causal inference. Written informed consent was obtained from all the participants from SEER or UKB according to the established standard of the studies. The current study design was reviewed by the Institutional Review Board at Ruijin Hospital (Shanghai, China). Genotyping and Quality Control GWAS genotyping array data with imputation and QC from UK Biobank release V3 was obtained (Bycroft et al., 2018). Briefly, a total of 488,377 participants (after quality control, QC) were genotyped in UKB using two similar genotyping arrays, the UK Biobank Lung Exome Variant Evaluation (UK BiLEVE with 807,411 markers, n=49,950) and the Applied Biosystems UK BiLEVE Axiom Array by Affymetrix (825,927 markers, n=438,427). These two arrays share 95% of the markers. Individuals were excluded if: (a) ancestry testing using principal component analysis (PCA) to evaluate the potential conflicts between self-reported ethnicity/race and the genetic ethnicity/race; (b) Poor call rate at the genotyping stage (n=968, 0.2%); (c) Mismatched results between self-reported gender and genetic gender (n=652, 0.13%). The genotype concordance rate was reported as>99.0%(Bycroft et al., 2018). A total of 93,095,623 autosomal SNPs were identified in 487,442 individuals(Bycroft et al., 2018).

Mendelian Randomization

The conceptual framework was illustrated in **Figure 1** and the MR study was reported in accordance with the STROBE-MR guideline(Skrivankova et al., 2021). Two-sample MR analyses were performed to evaluate the causality between exposures (a certain primary cancer, FPC) and outcomes (another primary cancer, SPC). We used previously identified disease risk-associated SNPs from the GWAS Catalog database(https://www.ebi.ac.uk/gwas/)(Buniello et al., 2019). SNPs selection was based on the following criteria: (1) SNPs were from a single GWAS that identified the largest number of risk-associated SNPs and were conducted in European ancestry; (2) SNPs reached genome-wide significant level (*P*<5×10⁻⁸); (3)

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

SNPs are independent of each other in terms of linkage disequilibrium (LD, $r^2 < 0.001$) and distance (>10,000 kb). MR analyses derive valid estimates where the following assumptions are met: (i) the SNPs are correlated with FPC, (ii) the SNPs affect SPC risk only through their effects on FPC and (iii) the SNPs are independent of any confounding factors for the association between FPC and SPC. For assumption (i), the strength of each instrument was measured using the F statistic and the proportion of the explained variance (R²), which was considered to be sufficient if the corresponding F-statistic is >10. For assumption (ii) and (iii), we searched the PhenoScanner database (available at http://www.phenoscanner.medschl.cam.ac.uk/phenoscanner)(Kamat et al., 2019; Staley et al., 2016) to examine whether SNPs were significantly associated with established risk factors for certain cancers, including BMI, smoking, alcohol intake and physical inactivity, and excluded those at $P<1.0\times10^{-5}$. Statistical power calculations performed online tool available were using an at https://shiny.cnsgenomics.com/mRnd/(Brion et al., 2013). The statistical power was to capture an OR of 1.20 or 0.80 per a standard deviation (SD) change in the cancer risk. Inverse-variance weighted MR (IVW-MR) and MR-Egger were used in the MR analyses(Burgess et al., 2019; Burgess & Thompson, 2017; Davies et al., 2018; Hemani et al., 2018). MR would be performed based on at least 4 SNPs. Briefly, these two methods are the most used MR methods to infer a causal relationship. IVW-MR is

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

based on a random effect model and is the most efficient with the greatest statistical power(Hemani et al., 2018). Potential bias as horizontal pleiotropy was evaluated and adjusted via MR-Egger(Burgess et al., 2019; Burgess & Thompson, 2017; Davies et al., 2018; Hemani et al., 2018). The causal inference was interpreted via IVW-MR results if the horizontal pleiotropic effect was not significant; otherwise, based on MR-Egger. A causal relationship will only be interpreted when a significant MR result was observed from MR analyses together with a significant association based on the SEER database. A series of sensitivity and robust analyses including leave-one-out, Radial MR(Bowden et al., 2019; Bowden et al., 2018) and CAUSE(Morrison et al., 2020) methods would be performed in case of concordant significant results. MR analyses were performed using the R package "TwoSampleMR", "MendelianRandomization", "RadialMR" and "cause". Statistical Analysis The multiple primary standardized incidence ratios (MP-SIR) were defined as the observed incidence of a second malignancy among cases previously diagnosed with a certain type of cancer divided by the expected incidence based on the SEER referent population (the SEER18 2000-2016 referent rate file). All the standardized incidence observed/expected (O/E) ratios (SIR) and the corresponding 95% confidence intervals (95% CI) were derived using the "MP-SIR" session of SEER*Stat (version

8.3.8)("Multiple Primary - Standardized Incidence Ratios - SEER*Stat.,"). Only the

non-Hispanic white population was included in the present study. We restricted a minimum 2-month latency period between the first and second primary diagnosis(Davis et al., 2014). Subgroup analyses were performed after stratifying by radiation therapy (received or not). All statistical analyses were performed using SEER*STAT and R software (4.1.2)(Team, 2021). A type I error of 0.05 (two-sided) was used to define statistical significance. Multiplicity effects were only considered during the selection of SNPs.

337 Reference 338 Bowden, J., Del Greco M, F., Minelli, C., Zhao, Q., Lawlor, D. A., Sheehan, N. A., 339 Thompson, J., & Davey Smith, G. (2019). Improving the accuracy of 340 two-sample summary-data Mendelian randomization: moving beyond the 341 NOME assumption. *International Journal of Epidemiology*, 48(3), 728-742. 342 https://doi.org/10.1093/ije/dyy258 343 344 Bowden, J., Spiller, W., Del Greco M, F., Sheehan, N., Thompson, J., Minelli, C., & 345 Davey Smith, G. (2018). Improving the visualization, interpretation and 346 analysis of two-sample summary data Mendelian randomization via the Radial 347 plot and Radial regression. *International Journal of Epidemiology*, 47(4), 348 1264-1278. https://doi.org/10.1093/ije/dyv101 349 350 Brion, M.-J. A., Shakhbazov, K., & Visscher, P. M. (2013). Calculating statistical 351 power in Mendelian randomization studies. International Journal of 352 Epidemiology, 42(5), 1497-1501. https://doi.org/10.1093/ije/dyt179 353 354 Buniello, A., MacArthur, J. A. L., Cerezo, M., Harris, L. W., Hayhurst, J., Malangone, 355 C., McMahon, A., Morales, J., Mountjoy, E., Sollis, E., Suveges, D., 356 Vrousgou, O., Whetzel, P. L., Amode, R., Guillen, J. A., Riat, H. S., 357 Trevanion, S. J., Hall, P., Junkins, H., Flicek, P., Burdett, T., Hindorff, L. A., 358 Cunningham, F., & Parkinson, H. (2019). The NHGRI-EBI GWAS Catalog of 359 published genome-wide association studies, targeted arrays and summary 360 statistics 2019. Nucleic Acids Research, 47(D1), D1005-D1012. 361 https://doi.org/10.1093/nar/gky1120 362 363 Burgess, S., Davey Smith, G., Davies, N. M., Dudbridge, F., Gill, D., Glymour, M. 364 M., Hartwig, F. P., Holmes, M. V., Minelli, C., Relton, C. L., & Theodoratou, 365 E. (2019). Guidelines for performing Mendelian randomization investigations. 366 Wellcome Open Research, 4, 186. 367 https://doi.org/10.12688/wellcomeopenres.15555.2 368 369 Burgess, S., & Thompson, S. G. (2017). Interpreting findings from Mendelian 370 randomization using the MR-Egger method. European Journal of 371 Epidemiology, 32(5), 377-389. https://doi.org/10.1007/s10654-017-0255-x 372 373 374 Bycroft, C., Freeman, C., Petkova, D., Band, G., Elliott, L. T., Sharp, K., Motyer, A., 375 Vukcevic, D., Delaneau, O., O'Connell, J., Cortes, A., Welsh, S., Young, A., 376 Effingham, M., McVean, G., Leslie, S., Allen, N., Donnelly, P., & Marchini, J.

377 (2018). The UK Biobank resource with deep phenotyping and genomic data. 378 Nature, 562(7726), 203-209. https://doi.org/10.1038/s41586-018-0579-z 379 380 Chattopadhyay, S., Sud, A., Zheng, G., Yu, H., Sundquist, K., Sundquist, J., Försti, A., 381 Houlston, R., Hemminki, A., & Hemminki, K. (2018). Second primary 382 cancers in non-Hodgkin lymphoma: Bidirectional analyses suggesting role for 383 immune dysfunction. International Journal of Cancer, 143(10), 2449-2457. 384 https://doi.org/10.1002/ijc.31801 385 386 Copur, M. S., & Manapuram, S. (2019). Multiple Primary Tumors Over a Lifetime. 387 Oncology (Williston Park, N.Y.), 33(7). 388 https://pubmed.ncbi.nlm.nih.gov/31365752 389 390 Davies, N. M., Holmes, M. V., & Davey Smith, G. (2018). Reading Mendelian 391 randomisation studies: a guide, glossary, and checklist for clinicians. BMJ 392 (Clinical Research ed.), 362, k601. https://doi.org/10.1136/bmj.k601 393 394 Davis, E. J., Beebe-Dimmer, J. L., Yee, C. L., & Cooney, K. A. (2014). Risk of 395 second primary tumors in men diagnosed with prostate cancer: a 396 population-based cohort study. Cancer, 120(17), 2735-2741. 397 https://doi.org/10.1002/cncr.28769 398 399 Feller, A., Matthes, K. L., Bordoni, A., Bouchardy, C., Bulliard, J.-L., Herrmann, C., 400 Konzelmann, I., Maspoli, M., Mousavi, M., Rohrmann, S., Staehelin, K., & 401 Arndt, V. (2020). The relative risk of second primary cancers in Switzerland: a 402 population-based retrospective cohort study. BMC Cancer, 20(1), 51. 403 https://doi.org/10.1186/s12885-019-6452-0 404 405 Hemani, G., Zheng, J., Elsworth, B., Wade, K. H., Haberland, V., Baird, D., Laurin, 406 C., Burgess, S., Bowden, J., Langdon, R., Tan, V. Y., Yarmolinsky, J., Shihab, 407 H. A., Timpson, N. J., Evans, D. M., Relton, C., Martin, R. M., Davey Smith, 408 G., Gaunt, T. R., & Havcock, P. C. (2018). The MR-Base platform supports 409 systematic causal inference across the human phenome. ELife, 7. 410 https://doi.org/10.7554/eLife.34408 411 412 Hortlund, M., Arroyo Mühr, L. S., Storm, H., Engholm, G., Dillner, J., & Bzhalava, D. 413 (2017). Cancer risks after solid organ transplantation and after long-term 414 dialysis. International Journal of Cancer, 140(5), 1091-1101. 415 https://doi.org/10.1002/ijc.30531 416 417 Italian cancer figures, report 2013: Multiple tumours. (2013). Epidemiologia E 418 Prevenzione, 37(4-5 Suppl 1). https://pubmed.ncbi.nlm.nih.gov/24259384

419 420 Kamat, M. A., Blackshaw, J. A., Young, R., Surendran, P., Burgess, S., Danesh, J., 421 Butterworth, A. S., & Staley, J. R. (2019). PhenoScanner V2: an expanded 422 tool for searching human genotype-phenotype associations. Bioinformatics 423 (Oxford, England), 35(22), 4851-4853. 424 https://doi.org/10.1093/bioinformatics/btz469 425 426 Morrison, J., Knoblauch, N., Marcus, J. H., Stephens, M., & He, X. (2020). 427 Mendelian randomization accounting for correlated and uncorrelated 428 pleiotropic effects using genome-wide summary statistics. Nature Genetics, 429 52(7), 740-747. https://doi.org/10.1038/s41588-020-0631-4 430 431 Multiple Primary - Standardized Incidence Ratios - SEER*Stat. 432 https://seer.cancer.gov/seerstat/mp-sir.html. 433 434 Number of Persons by Race and Hispanic Ethnicity for SEER Participants - SEER 435 Registries. https://seer.cancer.gov/registries/data.html#a7 436 437 Shalapour, S., & Karin, M. (2019). Pas de Deux: Control of Anti-tumor Immunity by 438 Cancer-Associated Inflammation. *Immunity*, 51(1), 15-26. 439 https://doi.org/10.1016/j.immuni.2019.06.021 440 441 Siegel, R. L., Miller, K. D., Fuchs, H. E., & Jemal, A. (2022). Cancer statistics, 2022. 442 CA: a Cancer Journal For Clinicians, 72(1). 443 https://doi.org/10.3322/caac.21708 444 445 Skrivankova, V. W., Richmond, R. C., Woolf, B. A. R., Yarmolinsky, J., Davies, N. 446 M., Swanson, S. A., VanderWeele, T. J., Higgins, J. P. T., Timpson, N. J., 447 Dimou, N., Langenberg, C., Golub, R. M., Loder, E. W., Gallo, V., 448 Tybiaerg-Hansen, A., Davey Smith, G., Egger, M., & Richards, J. B. (2021). 449 Strengthening the Reporting of Observational Studies in Epidemiology Using 450 Mendelian Randomization: The STROBE-MR Statement. JAMA, 326(16), 451 1614-1621. https://doi.org/10.1001/jama.2021.18236 452 453 Staley, J. R., Blackshaw, J., Kamat, M. A., Ellis, S., Surendran, P., Sun, B. B., Paul, D. 454 S., Freitag, D., Burgess, S., Danesh, J., Young, R., & Butterworth, A. S. 455 (2016). PhenoScanner: a database of human genotype-phenotype associations. 456 Bioinformatics (Oxford, England), 32(20), 3207-3209. 457 https://pubmed.ncbi.nlm.nih.gov/27318201 458 459 Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & 460 Bray, F. (2021). Global Cancer Statistics 2020: GLOBOCAN Estimates of

461 Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: a Cancer Journal For Clinicians, 71(3), 209-249. 462 463 https://doi.org/10.3322/caac.21660 464 465 Team, R. C. (2021). R: A language and environment for statistical computing. 466 https://www.R-project.org/. 467 468 Zheng, G., Sundquist, K., Sundquist, J., Försti, A., Hemminki, A., & Hemminki, K. 469 (2020). Rate differences between first and second primary cancers may outline immune dysfunction as a key risk factor. Cancer Medicine, 9(21), 8258-8265. 470 471 https://doi.org/10.1002/cam4.3454 472 473 **Data Availability** 474 Data used in this research are publicly available to qualified researchers on 475 application to GWAS catalog (https://www.ebi.ac.uk/gwas/), the SEER database 476 (https://seer.cancer.gov/) and UK Biobank (www.ukbiobank.ac.uk). 477 478 **Author Contributions** 479 R Na conceived and designed the study. XH Ruan, Da Huang processed and analyzed 480 the microarray data, performed different components of analysis and data 481 interpretations. YL Zhan provided technical support. JY Huang and JL Huang 482 provided material support. ATL Ng and JHL Tsu provided administrative support. 483 XH Ruan, D Huang and R Na wrote the manuscript. R Na made critical revision of 484 the manuscript for important intellectual content. All authors read and approved the 485 final manuscript. 486 487 **Competing interest**

489

490

491

492

493

494

495

496

497

498

499

500

501

502

503

504

505

506

507

508


The authors declare that there are no competing interests. Acknowledgement The current study contains a part of the capstone thesis by Rong Na for Master of Public Health at Johns Hopkins University School of Public Health (the results were updated based on the updated datasets); otherwise, the study content has never been published elsewhere. We would like to thank for the supervision from Professor Jianfeng Xu from NorthShore University Health System, IL USA, Professor William B. Issacs and Professor Bruce J. Trock from Johns Hopkins University, during Rong Na's capstone projects. We thank SEER program to approve our protocol and provide the custom datasets. We also thank the UK Biobank for access to the data (Project Number: 66813). **Funding information** This work was in supported by grants from National Natural Science Foundation of China (Grant No. 81972645), Innovative research team of high-level local universities in Shanghai, Shanghai Youth Talent Support Program, intramural grant of The University of Hong Kong to Dr. Rong Na, and Shanghai Sailing Program (22YF1440500) to Dr. Da Huang. All the funders had no role in study design, data collection, data analysis, interpretation, and writing of the report.

Figure legend

509

510

Figure 1. Study design and work flowchart.



- Abbreviation: SIR, standardized incidence ratio; GWAS, genome-wide significant
- 513 association.

511

512

514

Figure 2. Heat-map of SIR for First primary cancers (FPC, horizontal, cancer

listed in the bottom) and second primary cancers (SPC, vertical, cancer listed on

the right) in the SEER 18 registry (2000-2016).

515

516

517


519

520

521

522

523



The SIR scale is shown in the right corner. Only significant associations (95% confidence intervals not overlapping with 1.00) were included; SIRs of the insignificant or concordant associations were assigned as 1. Abbreviations: SIR, standardized incidence ratios; FPC, first primary cancers; SPC, second primary cancers.

Table 1. Summary of the cancer-specific instrument variables used in this study (European ancestry).

Cancer type	GWAS Source	PMID	Number of SNPs ^a	Cases	Total population	Variance explained, R ² , %	F-statistics
Oral and pharynx	GCST003857	27749845	7	6,034	12,619	2.22	283.68
Larynx	GCST010285	32276964	1^{b}	394	4,887	0.28	13.72
Esophagus	GCST003740	27527254	5	10,279	27,438	0.72	198.94
Stomach	GCST002990	26098866	1 ^b	2,043	202,533	0.02	34.44
Colon and rectum	GCST003017	26151821	8	18,299	37,955	0.89	340.75
Pancreas	GCST005434	29422604	14	9,040	21,536	4.28	962.28
Melanoma	GCST004142	28212542	17	6,628	293,193	0.29	852.68
Lung	GCST004748	28604730	7	29,266	85,716	0.55	474.00
Male Breast	GCST011526	32785646	2^{b}	2,190	6,836	1.27	87.91
Female Breast	GCST004988	29059683	104	122,977	228,951	4.95	11917.81
Cervix uteri	GCST004833	28806749	1^{b}	2,866	9,347	0.45	42.24
Ovary	GCST002748	25581431	9	18,530	69,745	1.16	818.42
Prostate	GCST006085	29892016	71	79,148	140,254	5.47	8111.66
Bladder	GCST002240	24163127	7	2,305	6,206	8.46	572.81
Kidney	GCST004710	28598434	8	10,784	31,190	1.11	349.99

Thyroid	GCST004144	28195142	6	3,001	290,551	0.10	290.83
Myeloma	GCST004483	27363682	13	9,866	249,054	0.31	774.24

^a Number of SNPs included in the final calculation of PRS in our study; not necessarily the total number of SNPs from the source due to the filtering steps discussed in the main text and germline data availability; ^b MR would be performed based on at least 4 SNPs.

Note: See Additional file and supplementary materials: Table S18 for the list of SNPs included in the final calculation for each phenotype.

No study found in European: bone and joint, brain, liver, small intestine, gallbladder, renal pelvis and ureter;

⁵²⁹ Heterogeneity: lymphoma, leukemia;

Too few SNPs: larynx, stomach, male breast cancer.

Table 2. Concordant causality between Mendelian randomization results and SEER analysis.

Cancer type	Cancer type (second primary cancer)					
(first primary cancer)	Positive Causality	Negative Causality	No Causality (statistical power≥0.80)			
Oral and pharynx	Non-hodgkin lymphoma	-	Female breast, Prostate			
Esophagus	-	-	-			
Colon and rectum	-	-	-			
Pancreas	Small intestin	-	Melanoma			
Melanoma	Female breast	-	Colon and Rectum			
Lung	-	Female Breast	-			
Female Breast	-	-	-			
Ovary	Soft tissue	-	-			
Prostate	-	Colon and Rectum	Non-hodgkin lymphoma			
Bladder	-	-	Female breast, Non-hodgkin lymphoma			
Kidney	Lung and Bronchus, Melanoma, Non-hodgkin lymphoma, Myeloma	-	-			
Thyroid	-	-	-			
Myeloma	-	Lung and Bronchus	-			

See Additional file: Table S20 for unconcordant causality result; Table S21-S33 for the details of Mendelian randomization results (IVW and MR-Egger).

Table 3. Sensitivity and robust analysis of the concordant causality with outlier-filtering approaches.

Exp-out	Radial IVW		Radial MR-F	Egger	CAUSE		
	OR (95%CI)	P	OR (95%CI)	P	OR (95%CI)	P	
Oropharynx-NHL	1.21 (1.13-1.30)	6.00×10 ⁻³	1.21 (1.13-1.30)	0.52	1.17 (1.05-1.31)	8.90×10 ⁻³	
Pancreas-Intestin	1.05 (0.83-1.32)	0.69	2.39 (0.91-6.31)	0.10	1.03 (0.79-1.35)	1.00	
Melanoma-Breast	1.08 (1.00-1.15)	0.06	1.05 (0.84-1.32)	0.69	1.04 (0.95-1.16)	0.75	
Lung-Breast	0.86 (0.79-0.93)	9.76×10^{-3}	0.77 (0.54-1.08)	0.19	0.89 (0.76-1.04)	0.23	
Ovary-Soft	1.39 (1.22-1.58)	1.07×10^{-3}	1.3 (0.74-2.29)	0.39	1.36 (1.16-1.58)	0.01	
Prostate-CRC	1.00 (0.95-1.04)	0.94	0.88 (0.80-0.98)	0.02	0.99 (0.93-1.04)	0.99	
Kidney-Lung	1.17 (1.08-1.27)	6.60×10^{-3}	0.94 (0.62-1.43)	0.78	1.16 (1.02-1.31)	0.05	
Kidney-Melanoma	1.33 (1.02-1.73)	0.04	0.56 (0.18-1.80)	0.37	1.25 (0.96-1.73)	0.51	
Kidney-NHL	1.25 (1.11-1.40)	7.87×10^{-3}	1.33 (0.72-2.46)	0.39	1.20 (0.99-1.43)	0.09	
Kidney-Myeloma	1.72 (1.21-2.45)	0.02	0.43 (0.11-1.77)	0.29	1.49 (1.04-2.34)	0.02	
Myeloma-Lung	0.92 (0.86-0.98)	0.02	1.09 (0.79-1.51)	0.61	0.93 (0.86-1.00)	0.21	

Abbreviation: IVW, Inverse variance weighted; CAUSE, Causal Analysis Using Summary Effect estimates; OR, odds ratio; CI, confidence interval; exp, exposure; out, outcome; NHL, non-hodgkin lymphoma; CRC, colorectal cancer.